Skip to content

Income Tax at other companies

Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$12K+50.0%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$64K+23.1%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$104M+8.0%
Incyte logo
IncyteINCY
$40.27M-47.0%

Other financials

Income statement

See full
Revenue$900.0K+12.5%
Operating income-$47.9M-80.1%
Net income-$47.6M-75.6%
EPS (diluted)-$0.11+57.7%

Balance sheet

See full
Cash & equivalents$229.2M+1,668%
Total debt$6.1M-15.7%
Total equity$207.9M+7,069%
Total assets$266.4M+427%

Cash flow

See full
Operating cash flow-$49.1M-149%
CapEx$400.0K
Free cash flow-$49.5M-151%

Valuation

See full
Market cap$923.31M+259%
Enterprise value$700.21M+179%
P/S159.6×+87.1×

Profitability

See full
Operating margin-2,910.4%-265pp
Net margin-2,895.4%-257pp
FCF margin-2,619.5%+69.9pp

Returns & leverage

See full
Return on equity-158.9%-26.4pp
Debt / equity-2.5×
Current ratio4.8×+4.0×

Where this comes from

Reported directly by DBV Technologies in its filing.

Tagged under the XBRL concept us-gaap:IncomeTaxExpenseBenefit.

The official record: DBV Technologies’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about DBV Technologies's income tax.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is DBV Technologies's income tax?
DBV Technologies (DBVT) reported income tax of $200K in Q1 2026.
What is the long-term trend for DBV Technologies's income tax?
Over 2 years (2021 to 2025), DBV Technologies's income tax has grown at a 10.2% compound annual growth rate (CAGR), from -$404K to $491K.
What does income tax mean?
Total income tax expense (current + deferred) recognized in the income statement, representing the company's total tax obligation on pre-tax income.